Prostate Cancer: A Look at Promising Clinical Trials
- سال انتشار: 1403
- محل انتشار: دومین کنگره بین المللی کنسرژنومیکس
- کد COI اختصاصی: ICGCS02_061
- زبان مقاله: انگلیسی
- تعداد مشاهده: 100
نویسندگان
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
چکیده
Prostate cancer (PCa) is a significant public health concern, affecting millions of men globally. It is particularly prevalent in North America, Europe, and Australia, with incidence rates increasing. While significant advancements have been made in PCa treatment, further research is critical to improve outcomes and enhance quality of life for patients. Clinical trials play a central role in driving progress in this field, serving as a platform for rigorous evaluation of novel therapies and optimization of existing approaches. Methods: This review examines the critical role of clinical trials in advancing PCa treatment. The systematic, phased approach of clinical trials is outlined, highlighting the three primary stages: Phase I trials focus on establishing the safety of a new therapy and determining the optimal dosage for further investigation; Phase II trials assess the effectiveness of the treatment and further refine the optimal dosage for larger studies; and Phase III trials, considered the most rigorous, compare the new treatment to standard care to definitively establish its efficacy. Findings: Clinical trials have significantly contributed to advancements in PCa treatment. These trials have led to the development of novel therapies, including targeted therapies, immunotherapies, and novel combinations of treatments. Furthermore, trials have helped refine existing treatments, making them more effective and reducing side effects. This has contributed to a deeper understanding of PCa biology, paving the way for more personalized and targeted approaches. Clinical trials are essential for driving innovation, understanding, optimization, and ethical conduct in PCa research, ultimately contributing to improved patient outcomes. Conclusion: Clinical trials remain a vital force in the battle against PCa. Continued research, innovative trial designs, and the participation of volunteers are crucial for achieving further breakthroughs in this field. By fostering collaboration, embracing new technologies, and focusing on a patient-centered approach, we can work toward a future where PCa is more effectively managed and treated, leading to improved quality of life for men affected by this disease.کلیدواژه ها
Prostate cancer, Clinical trials, Cancer treatment, medical research, Personalized medicineمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.